STOCK TITAN
  1. Home
  2. Sec-filings
  3. TARS
  4. [Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity

Tarsus (TARS) CEO Bobak Azamian granted stock options and RSUs with multi-year vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tarsus Pharmaceuticals reported that President, CEO and Board Chair Bobak R. Azamian received new equity awards. He was granted a stock option for 96,723 shares at an exercise price of $0.00 per share and 60,776 Restricted Stock Units, both recorded as awards rather than open-market purchases.

The option will vest 25% on March 5, 2027, with the remaining shares vesting in equal monthly installments over the next three years, subject to his continuous service. The RSUs will vest in four equal annual installments on March 15 of 2027, 2028, 2029 and 2030, also contingent on continued service.

Positive

  • None.

Negative

  • None.
Insider Azamian Bobak R.
Role President/CEO and Board Chair
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 96,723 $0.00 --
Grant/Award Restricted Stock Units 60,776 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 96,723 shares (Direct); Restricted Stock Units — 60,776 shares (Direct)
Footnotes (1)
  1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Azamian Bobak R.
(Last) (First) (Middle)
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
(Street)
IRVINE CA 92618
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President/CEO and Board Chair
3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $74.9 03/05/2026 A 96,723 (1) 03/04/2036 Common Stock 96,723 $0 96,723 D
Restricted Stock Units (2) 03/05/2026 A 60,776 (3) (3) Common Stock 60,776 $0 60,776 D
Explanation of Responses:
1. 25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
3. The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.
Remarks:
/s/ Jeffrey Farrow, Attorney-in-Fact 03/09/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Tarsus Pharmaceuticals (TARS) report for Bobak R. Azamian?

Tarsus Pharmaceuticals reported that Bobak R. Azamian received equity awards, including a stock option for 96,723 shares and 60,776 Restricted Stock Units. Both awards were granted at an exercise or acquisition price of $0.00 per share and are subject to future vesting conditions tied to continued service.

How do the new stock options for Tarsus (TARS) CEO Bobak R. Azamian vest?

The stock option for 96,723 shares vests 25% on March 5, 2027. The remaining 75% vests in equal monthly installments over the following three years, provided Bobak R. Azamian continues serving the company throughout this vesting period.

What are the terms of the Restricted Stock Units granted to Tarsus (TARS) CEO?

Bobak R. Azamian received 60,776 Restricted Stock Units, each representing a right to one Tarsus common share. These RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029 and 2030, conditioned on his continuous service with the company.

Do the reported Tarsus (TARS) insider grants involve cash purchases of shares?

No, the reported grants are equity awards, not cash purchases. The stock option for 96,723 shares has an exercise price of $0.00 per share, and the 60,776 Restricted Stock Units are contingent rights to receive shares, both subject to vesting requirements.

Who is the insider involved in the latest Tarsus Pharmaceuticals (TARS) Form 4 filing?

The insider is Bobak R. Azamian, who serves as President, CEO and Board Chair of Tarsus Pharmaceuticals. The filing reports equity awards granted to him, including stock options and Restricted Stock Units with multi-year vesting schedules tied to his ongoing service.